About this Research Topic
The aim of this collection is to improve the study and biological understanding of resident and infiltrating myeloid responses across CNS pathology. In doing this we will attempt to:
1. Contribute to our growing understanding of the functional versatility of unique myeloid subsets in CNS perturbation.
2. Contribute to our understanding of the phenotype diversity of myeloid signatures across CNS disease.
3. Elucidate unique and shared responses of microglia, border-associated macrophages and bone marrow-derived myeloid cells in the diseased CNS.
4. Define the protective and pathological processes coordinated by resident and infiltrating myeloid cells in CNS pathology.
5. Identify pathological mechanisms that could be targeted (or protective processes that could be enhanced) for CNS disease resolution.
6. Develop novel therapies that can be used to target pathological myeloid processes.
7. Contribute to the development of new tools, procedures, identification markers, depletion agents and computational methods that enhance the study and manipulation of myeloid cells in disease.
This research topic welcomes reviews, short reports and original research reporting new research or technical (including new methods) findings. These should focus on enhancing the understanding and/or investigation of myeloid cells in disease. These can include the study of human and mouse microglia, border-associated macrophages and/or monocyte-derived cells in neurodegeneration, viral infection, ischemia, traumatic brain injury and other experimental CNS perturbations.
Modalities, data types and analysis can include:
• high-dimensional cytometric profiling of myeloid cells using flow, spectral and/or mass cytometry
• panel optimisation and/or new tissue processing methods
• Bulk and single-cell RNA sequencing methods and findings
• Histology: immunohistochemistry and imaging mass cytometry
• Meta-analysis of previously published datasets
Research publications must include in vivo and/or ex vivo investigation of myeloid cells using murine or human tissues.
Conflict of Interest Statement: NJCK is a coauthor on a patent application for immune-modifying nano-particles (#WO2012065153A2) and owns stock in Cour Pharmaceutical Development Inc and enCour, the license holder of the patent application. He is on the Scientific Advisory Board of Myeloid Therapeutics and owns stock in this company. No other Conflicts are declared
Keywords: Microglia, Monocyte-derived cells, Myeloid cells, Inflammation, Immunopathology, Neuroinflammation, CNS pathology
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.